After decades of limited research and legal roadblocks to medical and recreational use, psychedelic drugs are rapidly remerging as treatments of interest in psychiatry. We interviewed two experts in the field.
To learn more about the overlapping crises of the opioid epidemic and the COVID-19 pandemic, Psychiatry Advisor interviewed pain specialist Paul J. Christo, MD, MBA, the Director of the Multidisciplinary Pain Fellowship Program at Johns Hopkins Hospital in Baltimore, Maryland.
Adolescents’ psychological challenges are increasingly entangled with their experiences online and virtual interactions with their peers on social media. We look at what this means during the COVID-19 pandemic.
After a decades-long global stop of research on psychedelic drugs, investigation of psychedelics in the context of psychiatric disorders is yielding some positive results.
COVID-19 has caused disruptions all across the world. In this piece, we take a look at what working during the pandemic has been like for psychiatric residents, as well as opportunities that the current situation has offered for learning.
The APA and AACAP offered 8 recommendations for school reopening plans.
In a multivariable logistic regression, PN and LSC were associated with having 1 or more mental health disorders.
We recently interviewed Jack Turban, MD, a resident physician in psychiatry at The Massachusetts General Hospital in Boston, where he researches the mental health of transgender youth.
Although the mechanisms remain unknown, antidepressants seem to have a protective effect in relation to the role of depression as a risk factor for psoriasis.
Maintaining a consistent sleep-wake schedule, including exposure to bright light in the morning and avoidance of it at night, may be the most reliable way to reduce pandemic-induced sleep problems.
